Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

Cesare Gridelli; Filippo de Marinis; Jean-Louis Pujol; Martin Reck; Rodryg Ramlau; Barbara Parente; Thierry Pieters; Gary Middleton; Jesus Corral; Katherine Winfree; Symantha Melemed; Anna Zimmermann; William John; Julie Beyrer; Nadia Chouaki; Carla Visseren-Grul; Luis G Paz-Ares

doi:10.1097/JTO.0b013e318267cf84

Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

Cesare Gridelli
, Filippo de Marinis
, Jean-Louis Pujol
, Martin Reck
, Rodryg Ramlau
, Barbara Parente
, Thierry Pieters
, Gary Middleton
, Jesus Corral
, Katherine Winfree
, Symantha Melemed
, Anna Zimmermann
, William John
, Julie Beyrer
, Nadia Chouaki
, Carla Visseren-Grul
, Luis G Paz-Ares

Cancer and Genomic Sciences

Research output: Contribution to journal › Article › peer-review

43 Citations (Scopus)

Abstract

In a phase III, randomized, double-blind study (PARAMOUNT), maintenance pemetrexed demonstrated significant benefit in advanced non-small-cell lung cancer (NSCLC). We present safety, resource use, and quality of life (QoL) results.

Original language	English
Pages (from-to)	1713-21
Number of pages	9
Journal	Journal of Thoracic Oncology
Volume	7
Issue number	11
DOIs	https://doi.org/10.1097/JTO.0b013e318267cf84
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1097/JTO.0b013e318267cf84

Fingerprint

Dive into the research topics of 'Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this

Gridelli, C., de Marinis, F., Pujol, J.-L., Reck, M., Ramlau, R., Parente, B., Pieters, T., Middleton, G., Corral, J., Winfree, K., Melemed, S., Zimmermann, A., John, W., Beyrer, J., Chouaki, N., Visseren-Grul, C., & Paz-Ares, L. G. (2012). Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Journal of Thoracic Oncology, 7(11), 1713-21. https://doi.org/10.1097/JTO.0b013e318267cf84

@article{4bd0218fa7a94059ba7e76521f1fe114,

title = "Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer",

abstract = "In a phase III, randomized, double-blind study (PARAMOUNT), maintenance pemetrexed demonstrated significant benefit in advanced non-small-cell lung cancer (NSCLC). We present safety, resource use, and quality of life (QoL) results.",

author = "Cesare Gridelli and \{de Marinis\}, Filippo and Jean-Louis Pujol and Martin Reck and Rodryg Ramlau and Barbara Parente and Thierry Pieters and Gary Middleton and Jesus Corral and Katherine Winfree and Symantha Melemed and Anna Zimmermann and William John and Julie Beyrer and Nadia Chouaki and Carla Visseren-Grul and Paz-Ares, \{Luis G\}",

year = "2012",

doi = "10.1097/JTO.0b013e318267cf84",

language = "English",

volume = "7",

pages = "1713--21",

journal = "Journal of Thoracic Oncology",

issn = "1556-1380",

publisher = "Lippincott Williams and Wilkins",

number = "11",

}

Gridelli, C, de Marinis, F, Pujol, J-L, Reck, M, Ramlau, R, Parente, B, Pieters, T, Middleton, G, Corral, J, Winfree, K, Melemed, S, Zimmermann, A, John, W, Beyrer, J, Chouaki, N, Visseren-Grul, C & Paz-Ares, LG 2012, 'Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer', Journal of Thoracic Oncology, vol. 7, no. 11, pp. 1713-21. https://doi.org/10.1097/JTO.0b013e318267cf84

Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. / Gridelli, Cesare; de Marinis, Filippo; Pujol, Jean-Louis et al.
In: Journal of Thoracic Oncology, Vol. 7, No. 11, 2012, p. 1713-21.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Safety, resource use, and quality of life in paramount

T2 - a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

AU - Gridelli, Cesare

AU - de Marinis, Filippo

AU - Pujol, Jean-Louis

AU - Reck, Martin

AU - Ramlau, Rodryg

AU - Parente, Barbara

AU - Pieters, Thierry

AU - Middleton, Gary

AU - Corral, Jesus

AU - Winfree, Katherine

AU - Melemed, Symantha

AU - Zimmermann, Anna

AU - John, William

AU - Beyrer, Julie

AU - Chouaki, Nadia

AU - Visseren-Grul, Carla

AU - Paz-Ares, Luis G

PY - 2012

Y1 - 2012

N2 - In a phase III, randomized, double-blind study (PARAMOUNT), maintenance pemetrexed demonstrated significant benefit in advanced non-small-cell lung cancer (NSCLC). We present safety, resource use, and quality of life (QoL) results.

AB - In a phase III, randomized, double-blind study (PARAMOUNT), maintenance pemetrexed demonstrated significant benefit in advanced non-small-cell lung cancer (NSCLC). We present safety, resource use, and quality of life (QoL) results.

U2 - 10.1097/JTO.0b013e318267cf84

DO - 10.1097/JTO.0b013e318267cf84

M3 - Article

C2 - 23059776

SN - 1556-1380

VL - 7

SP - 1713

EP - 1721

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 11

ER -